Biocon Limited (BIOCON) — key facts
NSE-listed · Healthcare. Data as of 11 Nov 2026 (IST) from InvestSights.
Last close: ₹368.5 (+0.34% day change)
Key ratios
- P/E ratio
- 130.67
- P/B ratio
- 1.45
- ROE (%)
- 1.13
- ROCE (%)
- 3.02
- Debt/Equity
- 0.45
- Dividend yield (%)
- 0.18
- Market cap (₹ Cr)
- 60,002.47
Forensic checks
Piotroski F-Score: 6/9 · Altman Z-Score: 5.77 · Beneish M-Score: -2.4
InvestSights quality score
53.5/100 — Average (descriptive data-driven composite; not a recommendation)
Management guidance track record
- Biosimilars R&D spend as a percentage of revenue: guided 7–9%, delivered 6% (FY26) — exceeded guidance
- Liraglutide U.S. FDA approval: guided 1approval, delivered 1approval (FY26) — met guidance
Latest earnings call (Q1 FY27)
AI summary: The single most important signal from this call is Biocon's deliberate pivot from volume-led market share pursuit to margin-accretive, profitable growth — a strategic recalibration that management articulated repeatedly and with unusual consistency across all speakers. The biosimilar EBITDA margin of 25% in Q1 FY27, combined with Kedar's clarification that last year's 27%…
Full analysis on InvestSights
InvestSights is an analytics platform and is not SEBI-registered as a Research Analyst or Investment Adviser. All figures are educational, descriptive data — not investment advice. Consult a SEBI-registered adviser before investing.